ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.
Saved in:
| Title: | ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model. |
|---|---|
| Authors: | Vandyck K; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium. Electronic address: kvandyck@aligos.com., Abdelnabi R; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Gupta K; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Jochmans D; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Jekle A; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Deval J; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Misner D; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Bardiot D; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Foo CS; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Liu C; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Ren S; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Beigelman L; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Blatt LM; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Boland S; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Vangeel L; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Dejonghe S; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Chaltin P; Centre for Drug Design and Discovery (CD3), KU Leuven, Gaston Geenslaan 2, 3001 Leuven, Belgium; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Marchand A; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Serebryany V; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Stoycheva A; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Chanda S; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Symons JA; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Raboisson P; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., Neyts J; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: johan.neyts@kuleuven.be. |
| Source: | Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2021 May 28; Vol. 555, pp. 134-139. Date of Electronic Publication: 2021 Mar 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2104 (Electronic) Linking ISSN: 0006291X NLM ISO Abbreviation: Biochem Biophys Res Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
